Header Logo

Connection

Wendy Stevens to HIV Infections

This is a "connection" page, showing publications Wendy Stevens has written about HIV Infections.
Connection Strength

9,475
  1. Ten-year health impact, economic impact and return on investment of the South African molecular diagnostics programme for HIV, tuberculosis and SARS-CoV-2. BMJ Glob Health. 2024 Dec 03; 9(12).
    View in: PubMed
    Score: 0,263
  2. National Impact of SARS-CoV-2 Infection on HIV Virological Suppression in South Africa. J Acquir Immune Defic Syndr. 2023 12 15; 94(5):381-386.
    View in: PubMed
    Score: 0,246
  3. Tuberculosis testing patterns in South Africa to identify groups that would benefit from increased investigation. Sci Rep. 2023 11 27; 13(1):20875.
    View in: PubMed
    Score: 0,245
  4. Cross-municipality migration and spread of tuberculosis in South Africa. Sci Rep. 2023 02 15; 13(1):2674.
    View in: PubMed
    Score: 0,233
  5. Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory. Int J Infect Dis. 2021 Sep; 110:1-3.
    View in: PubMed
    Score: 0,207
  6. Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting. J Mol Diagn. 2020 10; 22(10):1225-1237.
    View in: PubMed
    Score: 0,195
  7. Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
    View in: PubMed
    Score: 0,192
  8. Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Clin Infect Dis. 2020 03 03; 70(6):1014-1020.
    View in: PubMed
    Score: 0,189
  9. Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
    View in: PubMed
    Score: 0,159
  10. Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa. J Clin Microbiol. 2017 08; 55(8):2491-2501.
    View in: PubMed
    Score: 0,157
  11. Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. Curr Opin HIV AIDS. 2017 03; 12(2):117-122.
    View in: PubMed
    Score: 0,154
  12. Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay. PLoS One. 2016; 11(12):e0168244.
    View in: PubMed
    Score: 0,152
  13. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,151
  14. Human Immunodeficiency Virus (HIV)-Infected Patients Accept Finger Stick Blood Collection for Point-Of-Care CD4 Testing. PLoS One. 2016; 11(8):e0161891.
    View in: PubMed
    Score: 0,148
  15. Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
    View in: PubMed
    Score: 0,143
  16. A High Burden Human Immunodeficiency Virus and Tuberculosis Resource Limited Setting, Gains from Including Xpert MTB/RIF in the Diagnostic Algorithm of Fluid Specimens Submitted for Exclusion of Lymphoma by Immunophenotypic Analysis. PLoS One. 2015; 10(8):e0134404.
    View in: PubMed
    Score: 0,138
  17. Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol. 2015 May; 53(5):1616-21.
    View in: PubMed
    Score: 0,134
  18. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
    View in: PubMed
    Score: 0,133
  19. Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med. 2014 Sep 08; 12:173.
    View in: PubMed
    Score: 0,130
  20. Time to reduce CD4+ monitoring for the management of antiretroviral therapy in HIV-infected individuals. S Afr Med J. 2014 Jun 20; 104(8):559-60.
    View in: PubMed
    Score: 0,128
  21. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
    View in: PubMed
    Score: 0,127
  22. Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks. PLoS One. 2013; 8(12):e85265.
    View in: PubMed
    Score: 0,123
  23. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. J Virol Methods. 2013 Dec; 194(1-2):300-7.
    View in: PubMed
    Score: 0,121
  24. Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. S Afr Med J. 2013 Jul; 103(7):436.
    View in: PubMed
    Score: 0,119
  25. Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing. J Clin Microbiol. 2012 Dec; 50(12):4083-6.
    View in: PubMed
    Score: 0,113
  26. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
    View in: PubMed
    Score: 0,104
  27. Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. J Acquir Immune Defic Syndr. 2011 Apr 15; 56(5):460-6.
    View in: PubMed
    Score: 0,102
  28. Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction. J Virol Methods. 2011 Mar; 172(1-2):78-80.
    View in: PubMed
    Score: 0,100
  29. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
    View in: PubMed
    Score: 0,099
  30. Should South Africa be performing nucleic acid testing on HIV enzyme-linked immunosorbent assay-negative samples? J Clin Microbiol. 2010 Sep; 48(9):3407-9.
    View in: PubMed
    Score: 0,097
  31. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S16-26.
    View in: PubMed
    Score: 0,095
  32. Challenges in implementing HIV load testing in South Africa. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S78-84.
    View in: PubMed
    Score: 0,095
  33. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
    View in: PubMed
    Score: 0,095
  34. Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):656-60.
    View in: PubMed
    Score: 0,095
  35. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr. 2009 Dec; 52(5):655-6.
    View in: PubMed
    Score: 0,093
  36. Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program. Pediatr Infect Dis J. 2009 Dec; 28(12):1123-5.
    View in: PubMed
    Score: 0,093
  37. Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme. BJOG. 2009 Dec; 116(13):1805-8.
    View in: PubMed
    Score: 0,092
  38. Slow accumulation of HIV resistance mutations: implications for resource-limited settings? J Infect Dis. 2009 Sep 01; 200(5):670-2.
    View in: PubMed
    Score: 0,091
  39. Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods. 2009 Dec; 162(1-2):218-22.
    View in: PubMed
    Score: 0,091
  40. Can oral fluid testing be used to replace blood-based HIV rapid testing to improve access to diagnosis in South Africa? J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5):646-8; author reply 648-9.
    View in: PubMed
    Score: 0,091
  41. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol. 2009 Oct; 47(10):3400-2.
    View in: PubMed
    Score: 0,091
  42. Ultra-high-throughput, automated nucleic acid detection of human immunodeficiency virus (HIV) for infant infection diagnosis using the Gen-Probe Aptima HIV-1 screening assay. J Clin Microbiol. 2009 Aug; 47(8):2465-9.
    View in: PubMed
    Score: 0,090
  43. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009 Jul; 47(7):2209-17.
    View in: PubMed
    Score: 0,089
  44. Evaluating new CD4 enumeration technologies for resource-constrained countries. Nat Rev Microbiol. 2008 Nov; 6(11 Suppl):S29-38.
    View in: PubMed
    Score: 0,086
  45. Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis of HIV in infants. J Clin Microbiol. 2008 Dec; 46(12):3941-5.
    View in: PubMed
    Score: 0,086
  46. Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One. 2008 Apr 30; 3(4):e2043.
    View in: PubMed
    Score: 0,083
  47. Evaluation of the performance of the automated NucliSENS easyMAG and EasyQ systems versus the Roche AmpliPrep-AMPLICOR combination for high-throughput monitoring of human immunodeficiency virus load. J Clin Microbiol. 2007 Apr; 45(4):1244-9.
    View in: PubMed
    Score: 0,076
  48. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr. 2005 Apr 15; 38(5):615-7.
    View in: PubMed
    Score: 0,068
  49. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol. 2005 Feb; 43(2):857-61.
    View in: PubMed
    Score: 0,067
  50. Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
    View in: PubMed
    Score: 0,065
  51. Identifying acute HIV infection--a major new public health challenge. S Afr Med J. 2004 Jul; 94(7):531.
    View in: PubMed
    Score: 0,064
  52. Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection. Pediatr Infect Dis J. 2004 Feb; 23(2):173-6.
    View in: PubMed
    Score: 0,062
  53. Laboratory monitoring of HIV/AIDS in a resource-poor setting. S Afr Med J. 2003 Apr; 93(4):262-3.
    View in: PubMed
    Score: 0,059
  54. Cohort profile: the South African National Health Laboratory Service (NHLS) National HIV Cohort. BMJ Open. 2022 10 19; 12(10):e066671.
    View in: PubMed
    Score: 0,057
  55. The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis. PLoS Med. 2022 08; 19(8):e1004076.
    View in: PubMed
    Score: 0,056
  56. HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018. MMWR Morb Mortal Wkly Rep. 2021 May 28; 70(21):775-778.
    View in: PubMed
    Score: 0,052
  57. Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma. JCO Glob Oncol. 2021 04; 7:611-621.
    View in: PubMed
    Score: 0,051
  58. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020 08 01; 34(10):1559-1566.
    View in: PubMed
    Score: 0,049
  59. Monitoring viral load for the last mile: what will it cost? J Int AIDS Soc. 2019 09; 22(9):e25337.
    View in: PubMed
    Score: 0,046
  60. Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission. J Virol. 2019 07 01; 93(13).
    View in: PubMed
    Score: 0,045
  61. The Utility of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Assay in Detecting Abnormalities in Lipid Metabolism and Cardiovascular Risk in an HIV-Infected South African Cohort. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619883944.
    View in: PubMed
    Score: 0,044
  62. Impact of a borderless sample transport network for scaling up viral load monitoring: results of a geospatial optimization model for Zambia. J Int AIDS Soc. 2018 12; 21(12):e25206.
    View in: PubMed
    Score: 0,043
  63. Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance. Sci Rep. 2018 10 25; 8(1):15751.
    View in: PubMed
    Score: 0,043
  64. Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa. PLoS Med. 2018 06; 15(6):e1002589.
    View in: PubMed
    Score: 0,042
  65. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS. 2018 05 15; 32(8):1043-1051.
    View in: PubMed
    Score: 0,042
  66. A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. PLoS One. 2017; 12(8):e0181519.
    View in: PubMed
    Score: 0,040
  67. Diagnosis of opportunistic infections: HIV co-infections - tuberculosis. Curr Opin HIV AIDS. 2017 03; 12(2):129-138.
    View in: PubMed
    Score: 0,038
  68. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
    View in: PubMed
    Score: 0,038
  69. Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016. MMWR Morb Mortal Wkly Rep. 2016 Dec 02; 65(47):1332-1335.
    View in: PubMed
    Score: 0,038
  70. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis. 2017 01; 17(1):e26-e29.
    View in: PubMed
    Score: 0,038
  71. Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
    View in: PubMed
    Score: 0,038
  72. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
    View in: PubMed
    Score: 0,037
  73. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 09 15; 214(6):873-83.
    View in: PubMed
    Score: 0,037
  74. Improved Sensitivity of a Dual-Target HIV-1 Qualitative Test for Plasma and Dried Blood Spots. J Clin Microbiol. 2016 07; 54(7):1877-1882.
    View in: PubMed
    Score: 0,036
  75. Ensuring quality: a key consideration in scaling-up HIV-related point-of-care testing programs. AIDS. 2016 05 15; 30(8):1317-23.
    View in: PubMed
    Score: 0,036
  76. Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset. PLoS One. 2015; 10(12):e0145320.
    View in: PubMed
    Score: 0,035
  77. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015 Dec 03; 528(7580):S68-76.
    View in: PubMed
    Score: 0,035
  78. Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries. MMWR Morb Mortal Wkly Rep. 2015 Nov 27; 64(46):1287-90.
    View in: PubMed
    Score: 0,035
  79. CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis. J Int AIDS Soc. 2015; 18:20061.
    View in: PubMed
    Score: 0,035
  80. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health. 2015 Aug; 3(8):e450-e457.
    View in: PubMed
    Score: 0,034
  81. A meta-analysis of the performance of the Pima™ CD4 for point of care testing. BMC Med. 2015 Jul 25; 13:168.
    View in: PubMed
    Score: 0,034
  82. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. J Infect Dis. 2016 Feb 15; 213(4):551-5.
    View in: PubMed
    Score: 0,034
  83. CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. PLoS One. 2015; 10(3):e0115019.
    View in: PubMed
    Score: 0,034
  84. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis. 2015 Feb; 15(2):241-7.
    View in: PubMed
    Score: 0,033
  85. The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. J Immunol Methods. 2014 Jul; 409:21-30.
    View in: PubMed
    Score: 0,032
  86. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
    View in: PubMed
    Score: 0,032
  87. Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis. 2014 Sep 01; 59(5):706-15.
    View in: PubMed
    Score: 0,032
  88. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014; 9(3):e86461.
    View in: PubMed
    Score: 0,031
  89. Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
    View in: PubMed
    Score: 0,031
  90. Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One. 2014; 9(2):e85869.
    View in: PubMed
    Score: 0,031
  91. Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):289-93.
    View in: PubMed
    Score: 0,031
  92. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
    View in: PubMed
    Score: 0,031
  93. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82.
    View in: PubMed
    Score: 0,030
  94. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15; 207 Suppl 2:S70-7.
    View in: PubMed
    Score: 0,030
  95. Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots. J Clin Microbiol. 2013 Jun; 51(6):1899-905.
    View in: PubMed
    Score: 0,029
  96. A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013 Jun; 51(6):1757-61.
    View in: PubMed
    Score: 0,029
  97. Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013 Jan 14; 103(2):101-6.
    View in: PubMed
    Score: 0,029
  98. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
    View in: PubMed
    Score: 0,028
  99. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PLoS One. 2012; 7(8):e41166.
    View in: PubMed
    Score: 0,028
  100. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Aug 02; 367(5):399-410.
    View in: PubMed
    Score: 0,028
  101. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012 Sep; 55(5):737-45.
    View in: PubMed
    Score: 0,028
  102. Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. Clin Infect Dis. 2012 May; 54 Suppl 4:S261-5.
    View in: PubMed
    Score: 0,028
  103. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012 May; 54 Suppl 4:S294-9.
    View in: PubMed
    Score: 0,028
  104. HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
    View in: PubMed
    Score: 0,027
  105. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012 Jun; 54(11):1660-9.
    View in: PubMed
    Score: 0,027
  106. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr. 2012 Apr 01; 59(4):340-6.
    View in: PubMed
    Score: 0,027
  107. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44.
    View in: PubMed
    Score: 0,027
  108. Automated sequence analysis and editing software for HIV drug resistance testing. J Clin Virol. 2012 May; 54(1):30-5.
    View in: PubMed
    Score: 0,027
  109. Perspectives on introduction and implementation of new point-of-care diagnostic tests. J Infect Dis. 2012 May 15; 205 Suppl 2:S181-90.
    View in: PubMed
    Score: 0,027
  110. Performance evaluation of the Pima™ point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc. 2012 Jan 30; 15(1):3.
    View in: PubMed
    Score: 0,027
  111. Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study. BMC Pediatr. 2011 Nov 21; 11:104.
    View in: PubMed
    Score: 0,027
  112. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,027
  113. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,027
  114. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012 Apr; 12(4):307-17.
    View in: PubMed
    Score: 0,027
  115. Increased microbial translocation in = 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age. Pediatr Infect Dis J. 2011 Oct; 30(10):877-82.
    View in: PubMed
    Score: 0,026
  116. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):23-31.
    View in: PubMed
    Score: 0,026
  117. Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
    View in: PubMed
    Score: 0,026
  118. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
    View in: PubMed
    Score: 0,026
  119. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.
    View in: PubMed
    Score: 0,026
  120. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
    View in: PubMed
    Score: 0,026
  121. Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient. Virus Genes. 2010 Dec; 41(3):358-60.
    View in: PubMed
    Score: 0,025
  122. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):5-12.
    View in: PubMed
    Score: 0,025
  123. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb; 41(1):43-54.
    View in: PubMed
    Score: 0,025
  124. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010 Sep 13; 5(9):e12598.
    View in: PubMed
    Score: 0,025
  125. Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010 Sep 07; 13:33.
    View in: PubMed
    Score: 0,025
  126. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):95-101.
    View in: PubMed
    Score: 0,025
  127. FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One. 2010 Jul 23; 5(7):e11762.
    View in: PubMed
    Score: 0,024
  128. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,024
  129. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010 Jun 12; 375(9731):2092-8.
    View in: PubMed
    Score: 0,024
  130. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses. 2010 Apr; 26(4):489-93.
    View in: PubMed
    Score: 0,024
  131. Reply to 'Quantification of HIV-1 RNA on Dried Blood Spots' AIDS 24:475-6. AIDS. 2010 Mar 13; 24(5):785-6.
    View in: PubMed
    Score: 0,024
  132. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS. 2009 Nov 27; 23(18):2459-66.
    View in: PubMed
    Score: 0,023
  133. Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children. AIDS Res Hum Retroviruses. 2009 Nov; 25(11):1141-8.
    View in: PubMed
    Score: 0,023
  134. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010 Jan 14; 115(2):161-7.
    View in: PubMed
    Score: 0,023
  135. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009 Feb 20; 23(4):461-9.
    View in: PubMed
    Score: 0,022
  136. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses. 2008 May; 24(5):743-51.
    View in: PubMed
    Score: 0,021
  137. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008; 13(5):625-39.
    View in: PubMed
    Score: 0,020
  138. Low risk of contamination with automated and manual excision of dried blood spots for HIV DNA PCR testing in the routine laboratory. J Virol Methods. 2007 Dec; 146(1-2):397-400.
    View in: PubMed
    Score: 0,020
  139. Clinical performance of an in-house real-time RT-PCR assay using a fluorogenic LUX primer for quantitation of human immunodeficiency virus type-1 (HIV-1). J Virol Methods. 2007 Dec; 146(1-2):14-21.
    View in: PubMed
    Score: 0,020
  140. Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):322-30.
    View in: PubMed
    Score: 0,019
  141. Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory. Clin Vaccine Immunol. 2007 Feb; 14(2):201-3.
    View in: PubMed
    Score: 0,019
  142. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006 Oct; 3(10):e417.
    View in: PubMed
    Score: 0,019
  143. Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis. Clin Vaccine Immunol. 2006 Jan; 13(1):152-5.
    View in: PubMed
    Score: 0,018
  144. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005 Dec; 43(12):5950-6.
    View in: PubMed
    Score: 0,018
  145. A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15-24 in South Africa: results of the baseline survey. Trop Med Int Health. 2005 Oct; 10(10):971-80.
    View in: PubMed
    Score: 0,017
  146. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005 Aug 12; 19(12):1289-97.
    View in: PubMed
    Score: 0,017
  147. Good clinical laboratory practice (GCLP): the need for a hybrid of good laboratory practice and good clinical practice guidelines/standards for medical testing laboratories conducting clinical trials in developing countries. Qual Assur. 2003 Apr-Jun; 10(2):83-9.
    View in: PubMed
    Score: 0,015
  148. Tuberculosis in children dying with HIV-related lung disease: clinical-pathological correlations. Int J Tuberc Lung Dis. 2002 Sep; 6(9):806-13.
    View in: PubMed
    Score: 0,014
  149. Diagnosis of human immunodeficiency virus infection in perinatally exposed orphaned infants in a resource-poor setting. Pediatr Infect Dis J. 2000 Oct; 19(10):1014-5.
    View in: PubMed
    Score: 0,012
  150. COVID-19 lockdowns in low- and middle-income countries: Success against COVID-19 at the price of greater costs. S Afr Med J. 2020 06 19; 110(8):724-726.
    View in: PubMed
    Score: 0,012
  151. Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. J Clin Microbiol. 2018 09; 56(9).
    View in: PubMed
    Score: 0,011
  152. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016 Nov; 16(11):e267-e275.
    View in: PubMed
    Score: 0,009
  153. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,007
  154. The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301). PLoS One. 2012; 7(9):e42322.
    View in: PubMed
    Score: 0,007
  155. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. J Clin Virol. 2012 May; 54(1):21-5.
    View in: PubMed
    Score: 0,007
  156. Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sex Transm Infect. 2010 Feb; 86(1):46-50.
    View in: PubMed
    Score: 0,006
  157. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009; 14(5):619-29.
    View in: PubMed
    Score: 0,005
  158. Comparison of cervicovaginal lavage, cervicovaginal lavage enriched with cervical swab, and vaginal tampon for the detection of HIV-1 RNA and HSV-2 DNA in genital secretions. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):406-9.
    View in: PubMed
    Score: 0,005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.